Overview

A 21-item female tumor genetic panel covers a wide locus set relevant to breast, ovarian and related malignancies. For B2B procurement the decisive due-diligence is regulatory: a panel is only as trustworthy as the laboratory's accreditation, its validation evidence and the consistency of its reporting.

How It Works

Regulatory assurance starts with the laboratory's quality system, typically an ISO 15189 or equivalent medical-laboratory accreditation. The assay itself must be validated for analytical sensitivity, specificity and reproducibility on the exact 21 genes offered, using reference materials. A credible vendor publishes its limit of detection and its variant-classification rules, because two labs can report the same raw data differently if their interpretation pipelines diverge.

Indications

The panel supports inherited-risk evaluation in women, particularly those with breast or ovarian cancer in the family or with early presentation. It is a diagnostic-service product, so the regulatory expectation is that the report meets local in-vitro diagnostic rules and carries the responsible laboratory's identification. Buyers should confirm the intended-use statement matches how they plan to market the test.

Dosage & Administration

No dosage. The controllable parameters are sample type, turnaround time, sequencing depth and the reporting standard. Procurement should require a defined validation summary and a fixed variant-classification rubric. Specify the format of the final report, including whether benign, likely-benign, variant-of-uncertain-significance and pathogenic calls are separated clearly.

Storage & Sourcing

Regulatory strength also shows in sample handling. Kits should arrive with validated stabilisation and a documented transport condition, and the lab should retain extracted libraries under controlled storage. B2B buyers must secure a data-protection agreement and confirm audit rights, since accreditation bodies expect traceable records for every sample received and every report issued.

FAQ

Q: Which accreditation proves the lab is competent?

ISO 15189 or a national equivalent for medical laboratories is the recognised benchmark. Ask for the current scope certificate and confirm the 21 genes fall within it.

Q: How is assay validation demonstrated?

Through sensitivity, specificity and reproducibility studies on reference samples, plus a stated limit of detection. A vendor unwilling to share validation summaries is a compliance risk.

Q: Are reporting standards regulated?

Yes, in-vitro diagnostic reports must identify the responsible lab and follow local classification rules. Verify that the report format meets the destination market's requirements.

Q: What records should a buyer be able to audit?

Sample receipts, extraction logs, sequencing runs, variant calls and report issuance. Traceability from swab to report is the core of regulatory assurance.